

News Release

Corona del Mar, CA --- April 22, 2014



Immunogenx™

ImmunogenX has completed a Series A investment round

The funds will enable acquisition of key intellectual property and provide working capital

ImmunogenX™ has completed a Series A investment™ round with accredited private investors. These funds will be used to acquire key rights to a clinical diagnostic method developed by Prof. Chaitan Khosla at Stanford and to provide working capital. The diagnostic method CypCel™ is a patented investigational technology conceived and demonstrated by Prof. Chaitan Khosla at Stanford University. Flamentera acquired the rights to the technology from Stanford and funded a highly successful proof-of-concept clinical study (Moron et. al., Am J Gastroenterol 2013; 108: 1-8).

Dr. Jack A. Syage, CEO of ImmunogenX remarked “This investment round is critical to our growth aspirations and was fully subscribed and completed in a timely manner enabling us to execute on our business plan. We believe we are well positioned to be a leading clinical and diagnostic company focusing on huge unmet needs for improving the quality of life of individuals suffering from celiacs disease, an incurable ailment.”

ImmunogenX is currently developing a follow-on confirmatory clinical study (Phase II) for the diagnostic method that monitors the progressive improvement in the small intestinal health of celiac patients adhering to gluten-free diet, the only treatment protocol available to these individuals.

About ImmunogenX

“ImmunogenX” (a subsidiary of Immunogenics LLC) was founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors. ImmunogenX is developing new advanced diagnostic screening methods to help individuals with suspected gluten sensitivities and/or diagnosed with celiac disease. For disease management we are extending and commercializing a successful clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment. This is a unique capability for which there are no other effective diagnostics. For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

www.Immunogenx.com

For further information please contact

Jack A. Syage, PhD
CEO
714 357-0631
jsyage@immunogenx.com

“ImmunogenX™”, “Immunogenics™”, “CypCel™”, and “Allergenomics™” are trademarks of Immunogenics LLC